Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
344
resultados
Última actualización
12/11/2026 [07:09:00]
Resumen de: DE102025117473A1
Die Erfindung betrifft ein Verfahren für die Diagnose einer neurodegenerativen Krankheit eines Individuums, bei dem in-vitro in einer biologischen Probe des Individuums eine für die Diagnose der neurodegenerativen Krankheit charakteristische Expression eines Proteins mittels einer Analyse eines für die Expression des Proteins spezifischen Biomarkers bestimmt wird.Die Erfindung zeichnet sich dadurch aus, dass das Protein ausgewählt ist aus HMG-CoA Synthase, SERPINA3, Pyruvat-Carboxylase, SCP-2, Myosin light polypeptide 6 und/oder Heat shock protein 60.Die Erfindung betrifft zudem zwei pharmazeutische Erzeugnisse sowie ein Kit und eine Verwendung.
Resumen de: EP4837918A1
The present invention relates to a surface-functionalized optical element comprising an IR-transparent optical element, wherein at least a part of the surface of the IR-transparent optical element is surface-functionalized, wherein said surface functionalization comprises a surface attachment moiety covalently attached to the surface of the IR-transparent optical element, and wherein at least part of the surface attachment moieties is covalently attached to a spacer moiety comprising a poly(alkylene oxide), wherein at least part of the spacer moieties is covalently attached to a charge optimization moiety, wherein said charge optimization moiety comprises a functional group that is charged under conditions of use of the optical element and optionally a poly(alkylene oxide), wherein at least part of the charge optimization moiety is covalently attached to a linker moiety comprising a poly(alkylene oxide), wherein at least part of the linker moieties is covalently attached to a molecular probe. The invention further relates to a single chain variable fragment (scFv) that can be used as a molecular probe for the capture of alpha-synuclein as well as sensor elements and sensors comprising said surface-functionalized optical element and/or scFv, and methods and uses thereof.
Resumen de: EP4838226A1
0001 A method of quantifying plasmalogen includes: a measurement sample preparation step of mixing a specimen containing protein and plasmalogen with Schiff reagent, to obtain a measurement sample; a control sample preparation step of mixing the specimen with a solvent of the Schiff reagent, to obtain a control sample; a measurement step of measuring a degree of a first optical property of the measurement sample after reaction of the Schiff reagent with an aldehyde generated from a vinyl ether bond of the plasmalogen, and a degree of an optical property of the control sample; and a determination step of determining a plasmalogen concentration in the specimen by comparing a corrected degree obtained by correcting the degree of the first optical property with the degree of the optical property of the control sample, with a degree of a second optical property of a standard sample containing Schiff reagent and plasmalogen having a known concentration, the degree of the second optical property being obtained after reaction of the Schiff reagent with an aldehyde generated from a vinyl ether bond of the plasmalogen.
Resumen de: US20260347407A1
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, which is known to be a causative agent of Alzheimer's disease, and a composition for the treatment and prevention of Alzheimer's disease, comprising the peptide. When peptide SMA_04088-2 of the present invention is used, the fibrilization and oligomerization of amyloid beta can be prevented, and thus, the peptide SMA_04088-2 can be used in the treatment and prevention of amyloid diseases such as Alzheimer's disease. In addition, the peptide SMA_04088-2 can be used to detect amyloid beta, and thus can be used in the diagnosis of amyloid diseases such as Alzheimer's disease.
Resumen de: US20260345604A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: US20260347440A1
0000 The present disclosure provides monoclonal antibodies, and method of use thereof, for diagnosing and/or treating P. gingivalis infection and/or chronic diseases resulted from or associated with such infection. Specific antigen-antibody reaction regions on each P. gingivalis outer membrane protein are also identified and used for developing vaccines for prevention and treatment. The monoclonal antibodies of the present disclosure cross-react with different antigen regions of different P. gingivalis outer membrane protein. Animal models and diagnostic kits for serological evaluation and assessment of prognosis and treatment effectiveness after P. gingivalis infection are also provided.
Resumen de: US20260348949A1
0000 The present invention describes compositions for use in a proximity assay for detecting glycosylated molecules in a sample, and methods of use of the compositions for a proximity assay for detecting glycosylated molecules.
Resumen de: US20260347408A1
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, known to be a causative agent of Alzheimer's disease, and a composition for treating and preventing Alzheimer's disease, comprising the peptide. The peptide of the present invention can be used to prevent fibrosis and oligomerization of amyloid beta, and thus can be used for the treatment and prevention of amyloidogenic disease such as Alzheimer's disease. In addition, the peptide of the present invention can be used to detect amyloid beta, and thus can be used for the diagnosis of amyloidogenic diseases such as Alzheimer's disease.
Resumen de: US20260347849A1
0000 The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
Resumen de: US20260348976A1
The present invention relates to antibodies or binding fragments thereof for use in methods of identifying or diagnosing diseases associated with extracellular trap formation or release from cells, such as Neutrophil Extracellular Trap (NET)-associated pathologies or Eosinophil Extracellular Trap (EET)-associated pathologies.
Resumen de: US20260348983A1
The purpose of the present technology is to provide a technique for accurately determining cognitive impairment, cognitive decline, or risk of any of them. The present technology provides a determination supporting information generating method, that includes the steps: an index value calculating step of calculating, based on amounts of two or more biomarkers contained in a biological sample derived from a human, (I) a first index value indicating the presence or absence of cognitive impairment or cognitive decline in the human and (II) a second index value indicating the degree of progression of cognitive impairment or cognitive decline in the human; and a supporting information generating step of generating information that supports determination of cognitive impairment, cognitive decline, or risk of any of them, based on the first index value and the second index value.
Resumen de: US20260345011A1
0000 A method for measuring a physiological parameter of a user with a physiological measurement device. The physiological measurement device is applied to tissue of the user and causing light to be emitted from a light source physically incorporated into the housing. Performing an analysis of a first reflected light signal, a second reflected light signal, and a first ambient light signal. Based on the performed analysis, generating a processed output signal having a signal-to-noise ratio that is greater than a signal-to-noise ratio of the first reflected light signal, the processed output signal being associated with the physiological parameter of the user. Determining a measurement of the physiological parameter for the user using the processed output signal.
Resumen de: US20260348985A1
0000 Provided herein are methods of obtaining and applying measurements of metabolites to diagnosing ASD in a subject, particularly children, with high specificity and sensitivity. The metabolites can be measured in urine, serum, and whole blood samples.
Resumen de: US20260345531A1
0000 A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.
Resumen de: US20260347465A1
Provided herein are antibodies, including antigen-binding fragments thereof, that bind all or a portion thereof of CEA-CAM6, compositions containing such antibodies or antigen-binding fragments thereof, combinations of such antibodies or antigen-binding fragments thereof and methods of use. In particular embodiments, the antibodies or antigen-binding fragments thereof are used in methods of detecting the presence of CEACAM6 through imaging, including molecular, medical and diagnostic imaging.
Resumen de: WO2026230519A1
The present invention pertains to an Aquaporin-4 (AQP4) expression enhancer containing, as an active ingredient, naltrexone (CAS number: 16590-41-3) or a pharmaceutically acceptable salt thereof. The expression enhancer is useful for applications in maintaining or improving physiology functions involved in, suppressing progression of, and reducing the onset risk of, conditions related to hypofunction of the glymphatic system through regulation of expression of AQP4. The present invention also provides a screening method for selection of a substance useful for conditions related to hypofunction of the glymphatic system, by using, as an index, the expression level of AQP4 using human-derived astrocytes.
Resumen de: WO2026229758A1
This disclosure describes methods and compositions for detecting the presence of a RIMKLA autoantibody in a biological sample. Also provided are methods of treating subjects with progressive neurologic dysfunction, a paraneoplastic neurological disorder and/or cancer.
Resumen de: WO2026231288A1
A method for diagnosing an injury in a patient who was exposed to a blast includes obtaining a sample from the subject and extracting miRNA from the sample. The method further includes determining the miRNA in the sample. Finally, the method includes diagnosing a patient's injury based on the miRNA present in the sample.
Resumen de: WO2026231697A1
Described herein are methods of using a nanobiosensor to quantitatively measure expression of one or more genes associate with cognitive function in live cells. The methods include comparing the level of expression of the one or more gene associated with cognitive function to a library of gene expression levels to aide medical practitioners in determining the level of cognitive function and cause of cognitive decline in a patient.
Resumen de: WO2026230961A1
One embodiment of the present invention relates to: a marker composition for neurological diseases in a subject, comprising neurofilament light chain (NfL) and osteopontin (OPN) proteins or genes encoding the proteins; a diagnostic composition; a kit; and a method for providing information. The present inventors have identified that neuronal degeneration can be detected early, disease progression can be predicted, and a customized treatment strategy can be established using neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and osteopontin (OPN) biomarkers. In addition, it has been demonstrated that by applying multi-biomarker analysis, complex pathological mechanisms of neurodegenerative diseases can be more accurately reflected and diagnostic accuracy and sensitivity higher than those of a single biomarker can be ensured. Therefore, the multi-biomarker-based analysis method according to the present invention can be used as a useful tool for early diagnosis of neurodegenerative diseases, monitoring of disease progression, and evaluation of treatment response.
Resumen de: WO2026231884A1
The present disclosure provides a method of determining the presence and/or the quantity of a target in a sample and a method of determining the presence and/or the quantity of single nucleotide polymorphisms (SNPs) in a nucleic acid sample.
Resumen de: WO2026231940A1
The present disclosure relates to compositions comprising a sterile, stable leukapheresis product comprising nonexpanded populations of cells derived from peripheral blood via a leukapheresis procedure, wherein the leukapheresis product comprises one or more subpopulations of cells including T cells, B cells, NK cells, monocytes, macrophages, neutrophils, eosinophils, basophils, or mast cells, and wherein the leukapheresis product reliably, reproducibly and consistently preserves the quality, composition, and characteristics of the nonexpanded populations of cells and the subpopulations are preserved from batch to batch and from aliquot to aliquot within the batch. The present disclosure also relates to methods of preparing the sterile, stable leukapheresis product.
Resumen de: JP2026176820A
【課題】新規バイオマーカーを用いた多系統萎縮症の検査を補助するための情報を提供することを課題とする。【解決手段】多系統萎縮症の検査を補助するための情報を提供する情報提供方法であって、該情報提供方法は、被検者から採取した脳脊髄液に含まれる、キノリン酸および／またはキヌレン酸の含有量を測定する測定工程と、前記測定工程で得られたキノリン酸および／またはキヌレン酸の含有量の情報を提供する情報提供工程と、を含む情報提供方法。【選択図】図２
Resumen de: WO2026231779A1
Disclosed herein are methods for determining a risk of developing autism spectrum disorder (ASD) in newborns.
Nº publicación: WO2026231974A1 05/11/2026
Solicitante:
INTUS BIOSCIENCES LLC [US]
INTUS BIOSCIENCES, LLC
Resumen de: WO2026231974A1
Provided herein are methods and systems for noninvasive disease detection using high resolution microbiome profiling. Also provided are disease-associated bacterial and fungal sequence features used to detect, classify, or assess risk of diseases associated with microbiome dysbiosis.
BOPI
Sede Electrónica
